• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » The CenterWatch Monthly October 2010

The CenterWatch Monthly October 2010

October 1, 2010
CenterWatch Staff

Anticipating disruptions from sponsor M&As and consolidations

Teresa Sligh, M.D., was working on compounds with Schering-Plough when the project mysteriously stopped. Then she found out about the Merck-Schering Plough merger. Sligh’s experience isn’t that unusual. One of the often overlooked consequences of the recent flurry of merger and acquisition (M&A) activity in the biopharmaceutical industry is a disruption in relationships between drug sponsors and their service providers.

During the past two years, as numerous mergers have resulted in delays and cancellations of planned clinical trial work, the turmoil inside drug companies has made it difficult for many investigative sites to even reach their contacts. As the dust begins to settle from the recent biopharmaceutical M&As, investigative sites and CROs now worry about fewer opportunities going forward. They’ve redoubled their business development efforts to build new relationships with the biopharmaceuticals in order to replace those contacts who took new jobs or left the industry as a result of a merger.

By Karyn Korieth

 

More sites launching early-phase units

Wherever one looked this summer, it seemed another investigator site was launching a small, early-phase unit. This hot site trend of summer 2010 could, once it gathers more steam, constitute a threat to the big CROs that currently dominate the early-phase market.

Why now, as the economy begins to show signs of improvement, are so many sites jumping into this new business line? A panoply of factors have come together to make early-phase work attractive right now, paramount among them the changing nature of drug development and how that has trickled down to the site level.

Indeed, the dearth of promising new drug candidates has been widely publicized. Add to that the economic slowdown that has hit the industry hard. As a result, late-phase work at the site level has slowed, leaving sites scrambling. Luckily, at the same time, sponsors began to look at cutting costs by sending more candidates into something of a staged mix of phase I and IIa trials as a way to test efficacy immediately after testing safety.

By Suz Redfearn

Eye On Biogen Idec

The mission statement of Biogen Idec is to create new standards of care for unmet medical needs, particularly in the therapeutic fields of neurology, immunology, oncology, cardiopulmonary and hemophilia. Biogen Idec products are available in more than 90 countries for highly prevalent and disabling conditions such as multiple sclerosis, rheumatoid arthritis, Crohn’s disease and non-Hodgkin’s lymphoma.

To read the full articles for this issue or for more information on these and other breaking stories, please click here for subscription information.

 

Upcoming Events

  • 12Apr

    The Patient Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing